Advanced Malignancy
4
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
3
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
1100%
+ 3 programs with unclassified modality
Competitive Landscape
3 companies ranked by most advanced pipeline stage
CT
Chia Tai TianQing Pharmaceutical GroupChina - Lianyungang
1 program1
AnlotinibPhase 2Small Molecule1 trial
Active Trials
AmgenTHOUSAND OAKS, CA
2 programs2
AMG 228Phase 11 trial
Arm 1- Dose EscalationPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Chia Tai TianQing Pharmaceutical GroupAnlotinib
SynDevRxSDX-7320
AmgenAMG 228
AmgenArm 1- Dose Escalation
Clinical Trials (4)
Total enrollment: 125 patients across 4 trials
A Study of Anlotinib in Subjects With Advanced Malignancy
Start: Aug 2013Est. completion: Aug 2015
Phase 2Completed
A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors
Start: Feb 2016Est. completion: Dec 2019
Phase 1Completed
Safety Study of AMG 228 to Treat Solid Tumors
Start: Apr 2015Est. completion: Dec 201630 patients
Phase 1Terminated
A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors
Start: Aug 2009Est. completion: Apr 201995 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 companies competing in this space